Welcome to our dedicated page for ARDELYX SEC filings (Ticker: ARDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ARDELYX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ARDELYX's regulatory disclosures and financial reporting.
Ardelyx, Inc. filed a Form S-8 registering 10,000,000 shares of common stock for issuance under its Amended and Restated 2014 Equity Incentive Award Plan, resulting from an increase approved by stockholders on June 18, 2025.
The registration becomes effective upon filing, with sales to occur as awards under the plan are exercised and/or vest. This filing also references and builds on prior S-8 registrations for the 2014 Plan and the ESPP. Standard indemnification, incorporation-by-reference, and exhibit items are included.
Ardelyx reported Q3 results with total revenues of $110,329 thousand. Product sales, net were $105,515 thousand, led by IBSRELA at $78,158 thousand (up 92% year over year), while XPHOZAH contributed $27,357 thousand and reflected lower demand and price following its inclusion in the ESRD Prospective Payment System.
Operating expenses were $101,679 thousand. Net loss was $969 thousand. The quarter included $4,789 thousand of non-cash royalty revenue from Japan partner Kyowa Kirin, including a commercialization milestone of approximately $3.4 million tied to a ¥500.0 million trigger.
Cash, cash equivalents and short-term investments were $242,705 thousand as of September 30, 2025. Long-term debt was $202,138 thousand after drawing a $50,000 thousand Term E Loan on June 30, 2025, with options for an additional $100,000 thousand in committed term loans. Shares outstanding were 242,971,838 as of September 30, 2025.
Ardelyx, Inc. filed a current report stating that on October 30, 2025 it announced its financial results for the quarter ended September 30, 2025. The company furnished the full text of the related earnings press release as Exhibit 99.1, rather than treating it as filed, which affects how it may be used in future securities law filings. The report also notes the inclusion of an Inline XBRL cover page data file as Exhibit 104.
Ardelyx (ARDX) reported an initial Form 3 for a company officer. The filing lists 218,000 shares of Common Stock tied to restricted stock units, each RSU settling into one share upon vesting. It also discloses a stock option for 327,000 shares at an exercise price of $4.49, expiring on 07/14/2035.
Per the vesting terms, 25% of the option vests on 07/14/2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to continued service. The reporting person is identified as the company’s Chief Technical Operations Officer, and the event date is 08/01/2025.
Ardelyx (ARDX) insider ownership update: Chief Medical Officer Edward R. Conner filed an initial statement of beneficial ownership. He reports 302,260 shares of Common Stock (footnoted as RSUs that settle one-for-one upon vesting) held directly.
He also holds a stock option for 463,268 shares of Common Stock at an exercise price of $5.21, with an expiration date of 08/08/2035. Vesting is scheduled so that 25% vests on 08/08/2026, and the remainder vests in 36 equal monthly installments, subject to continued service. The filing was made by one reporting person in the capacity of Chief Medical Officer.
Ardelyx (ARDX) insider James Parker Brady filed an initial statement of beneficial ownership. He reports 166,000 shares of Common Stock (including RSUs that settle one share per RSU upon vesting) and a stock option for 250,000 shares at $3.93 expiring on 06/03/2035.
The option vests 25% on 06/03/2026, with the balance vesting in 36 equal monthly installments, subject to continued service. Brady serves as Chief Human Resources Officer. The event date is 06/18/2025.
Ardelyx appointed Sue Hohenleitner as chief financial officer and principal financial officer, effective November 4, 2025. She brings senior finance experience from Johnson & Johnson, including serving as CFO of J&J Innovative Medicine North America.
Her compensation includes an annual base salary of $550,000 and a target bonus equal to 45% of base salary, pro‑rated for fiscal 2025. Upon her employment commencement on October 13, 2025, she received a sign‑on bonus of $180,000 and a housing consideration payment of $150,000. Equity awards granted on October 13, 2025 comprise an option to purchase 578,104 shares at an exercise price of $5.01 per share, vesting over four years (25% after one year, then monthly over 36 months), and 146,896 restricted stock units vesting 25% on the first quarterly vest date after the one‑year anniversary, then quarterly over three years. The company plans to enter into its standard indemnification and change‑in‑control severance agreements with her.
Laura A. Williams, Chief Patient Officer of Ardelyx, Inc. (ARDX), reported multiple transactions on 08/26/2025 executed pursuant to a written plan under Rule 10b5-1. The filing shows an acquisition of 50,000 shares of common stock at $0.99 and two dispositions totaling 80,000 shares sold at a weighted average price of $6.121 (trades ranged $6.04–$6.20). Following these transactions, Ms. Williams beneficially owned 366,322 shares of common stock. The Form 4 also discloses a stock option with a $0.99 exercise price covering 50,000 shares that vests in 48 equal monthly installments beginning January 6, 2022, and expires January 6, 2032. The form is signed by an attorney-in-fact for Ms. Williams.
Mike Kelliher, Chief Business Officer and Director of Ardelyx, Inc. (ARDX), reported a sale of common stock on 08/21/2025. An automatic sell-to-cover executed upon the vesting of restricted stock units resulted in the disposition of 5,417 shares at $5.9317 per share to satisfy tax withholding. After the transaction, Kelliher beneficially owned 276,741 shares, reported as direct ownership. The Form 4 was filed as a single reporting person and signed by an attorney-in-fact on 08/28/2025.
Ardelyx, Inc. (ARDX) filed a Form 144 notifying the proposed sale of 80,000 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $484,800.00 and an approximate sale date of 08/26/2025 on NASDAQ. The filing shows the securities were acquired partly by exercise of stock options on 08/26/2025 (50,000 shares, paid in cash) and partly as restricted stock units on 02/19/2024 (30,000 shares). The filer also reported a prior sale of 6,261 shares on 08/21/2025 generating gross proceeds of $37,138.37. The filer certifies no undisclosed material adverse information and includes standard Rule 10b5-1 notice language.